Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, adiponectin over-expression in STZ rats decreased markers of endothelial dysfunction, a feature of diabetic nephropathy disease progression.
|
21521713 |
2011 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the possible association of ADIPOQ gene polymorphisms with T2DM and/or DN and whether they affect serum adiponectin levels in Egyptian population.
|
24469713 |
2014 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression and dysfunction of adiponectin and the cognate receptors are involved in diabetes and diabetic kidney disease (DKD), whereas angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) alleviate diabetic albuminuria and prevent development of DKD through upregulation of adiponectin expression.
|
28870804 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Renin-angiotensin-aldosterone system blockers, adiponectin receptor agonists, and PPAR agonists (e.g., tesaglitazar, thiazolidinediones, fenofibrate), which increase plasma adiponectin levels and adiponectin receptors expression, may be potential therapeutic drugs for the treatment of DKD.
|
28402446 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The LPD prevented the progression of diabetic status; this effect may have been associated with the reduction of FW and the elevation of plasma FGF21 and HMW adiponectin, as well as UCP1 expression in BAT, resulting in suppression of diabetic nephropathy.
|
29507597 |
2018 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Adiponectin levels are high in cases of diabetic nephropathy, but it remains unclear whether these high levels are a cause or a consequence of the disease.
|
20083470 |
2010 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Elevation of serum adiponectin and CD146 levels in diabetic nephropathy.
|
17490776 |
2007 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
These complimentary approaches have demonstrated that polymorphisms in the carnosinase 1 gene on chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 7p are likely associated with susceptibility to diabetic nephropathy.
|
17942768 |
2007 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of adiponectin in the development of diabetic nephropathy has not been elucidated, and the aim of the present study was to investigate the hypothesis that deletion of the gene for adiponectin would accelerate diabetic nephropathy in the Akita mouse.
|
25957229 |
2015 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overall significance for this variant (nominal P = 0.011) suggests that ADIPOQ might be involved in the development of diabetic nephropathy.
|
17065357 |
2006 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed a case-control study to examine whether the SNP276 of the adiponectin gene was also related to early diabetic nephropathy.
|
15334388 |
2004 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the therapeutic effects and the underlying mechanisms of adiponectin in early DN.
|
24816832 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that 11 genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8, ADIPOQ and IL-10 showed significant positive association with diabetic nephropathy.
|
25280384 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin exhibits its biological effects through adiponectin receptors (AdipoR1 and AdipoR2), which are distributed in the kidneys, and activation of those receptors could prevent or ameliorate diabetic nephropathy.
|
30135333 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy.
|
31245009 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose AdipoRon, an orally active synthetic adiponectin receptor agonist as a promising drug for restoration of DKD without inducing systemic adverse effects.
|
30974901 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis.
|
31572480 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
|
18496510 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin (ADP) may hold promise as a biomarker for diabetic nephropathy (DN).
|
30557306 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
|
29330340 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin protects against the development of albuminuria in rodent experiments and patients with diabetic kidney disease.
|
29894207 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy.
|
29462574 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we focus on the role of glomerular hypertrophy in the pathogenesis of DN and discuss the role of adiponectin in its prevention.
|
31048658 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that elevated adiponectin would be associated with early DKD in adults with type 1 diabetes.
|
27368123 |
2017 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adiponectin rs2241766T/G and rs17300593G/A rather than rs1501299G/T and rs266729C/G polymorphisms were associated with the risk of DN in T2DM, especially in the Caucasian population.
|
24825737 |
2015 |